# An Additional Study of NPC-22 in Healthy Adult Males

> **NCT04503863** · PHASE1 · COMPLETED · sponsor: **Nobelpharma** · enrollment: 32 (actual)

## Conditions studied

- Safety and Pharmacokinetics

## Interventions

- **DRUG:** NPC-22
- **DRUG:** NPC-22
- **DRUG:** NPC-22 Placebo

## Key facts

- **NCT ID:** NCT04503863
- **Lead sponsor:** Nobelpharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2020-11-06
- **Final completion:** 2021-12-28
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503863, "An Additional Study of NPC-22 in Healthy Adult Males". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04503863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*